paroxetine has been researched along with Parkinsonian Disorders in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campos, FL; Carvalho, MM; Coimbra, B; Lima, R; Pêgo, JM; Rodrigues, AJ; Rodrigues, C; Salgado, AJ; Sousa, N | 1 |
| Hannestad, J | 1 |
| Bishop, C; Buchta, W; Dickinson, SO; Eissa, S; Eskow Jaunarajs, KL; George, JA; Goldenberg, AA; Mohamed, M | 1 |
| Balcioglu, A; Tarazi, FI; Zhang, K | 1 |
| Bergamasco, B; Cicolin, A; Fattori, E; Guastamacchia, G; Lanotte, MM; Lopiano, L; Makrydakis, G; Mutani, R; Tavella, A; Terreni, A; Torre, E; Zibetti, M | 1 |
5 other study(ies) available for paroxetine and Parkinsonian Disorders
| Article | Year |
|---|---|
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion; Disease Models, Animal; Immunohistochemistry; Levodopa; Mood Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Rats; Rats, Wistar | 2013 |
Comment on "Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease".
Topics: Animals; Anti-Inflammatory Agents; Brain; Citalopram; Encephalitis; Humans; Inflammation; Lipopolysaccharides; Mice; Nerve Degeneration; Neurons; Oxidative Stress; Parkinsonian Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2010 |
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskinesia, Drug-Induced; Fluoxetine; Levodopa; Male; Parkinsonian Disorders; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2012 |
Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study.
Topics: Afferent Pathways; Amphetamine; Animals; Apomorphine; Binding, Competitive; Carrier Proteins; Denervation; Disease Models, Animal; Dopamine; Dopamine Agonists; Extracellular Matrix; Membrane Glycoproteins; Membrane Transport Proteins; Microdialysis; Neostriatum; Nerve Tissue Proteins; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Synaptic Transmission | 2003 |
Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients.
Topics: Antidepressive Agents; Disorders of Excessive Somnolence; Electric Stimulation Therapy; Female; Humans; Lorazepam; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Parkinsonian Disorders; Paroxetine; Polysomnography; Preoperative Care; Prospective Studies; Sertraline; Sleep Stages; Subthalamic Nucleus; Surveys and Questionnaires; Videotape Recording | 2004 |